[An evaluation of the clinical usefulness of amifostine (YM-08310), radioprotective agent. A double-blind placebo-controlled study. 2. Abdominal and pelvic tumors].

Main|Search|PHGKB




Last Posted: Aug 09, 2018

---

• [An evaluation of the clinical usefulness of amifostine (YM-08310), radioprotective agent. A double-blind placebo-controlled study. 2. Abdominal and pelvic tumors].
  Niibe H et al. Nihon Gan Chiryo Gakkai shi 1985 Jun 20(5) 994-1001
• Machine Learning
  NIH Catalyst, July 2018
• Cancer Scientists Have Ignored African DNA in the Search for Cures
  J Wapner, Newsweek, July 2018
• Methylation of the hsa-miR-124, SOX1, TERT, and LMX1A genes as biomarkers for precursor lesions in cervical cancer.
  Rogeri Caroline Domingues et al. Gynecologic oncology 2018 Jun
• Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer.
  Ngoi N Y L et al. Gynecologic oncology reports 2018 May 241-5
• Study Shows Experimental Screening Test Can Detect Endometrial and Ovarian Cancers
  NCI, May 2018
• Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center.
  Sharabi Andrew et al. The oncologist 2017 Jun 22(6) 631-637
• Cancer disparities 
• Personalized cancer screening: helping primary care rise to the challenge.
  Selby Kevin et al. Public health reviews 2018 394
• Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population.
  Dinh Tuan A et al. Cancer prevention research (Philadelphia, Pa.) 2011 Jan 4(1) 9-22

more